LOXL2 is a prognosis biomarker and a potential therapeutic target in intrahepatic cholangiocarcinoma. (April 2016) - Bergeat, D.; Fautrel, A.; Turlin, B.; Merdrignac, A.; Rayar, M.; Meunier, B.; Clement, B.; Boudjema, K.; Coulouarn, C.; Sulpice, L.